Vival time PFS Variables predictor score Surgical outcome (Sub vs Optimal
Vival time PFS Variables buy LDN193189 predictor score Surgical outcome (Sub vs Optimal) Stage(IV vs II II) Age OS predictor score Surgical outcome (Sub vs Optimal) Stage (IV vs II II) Age Cyclophosphamide TCGA-448 (n = 27) OS predictor score Surgical outcome (Sub vs Optimal) Stage (IV vs II II) Age Topotecan TCGA-test (n = 53) OS predictor score Surgical outcome (Sub vs Optimal) Stage (IV vs II II) Age Hazard ratio (95 CI) 0.515(0.332, 0.798) 1.099(0.821,1.472) 1.14(0.804, 1.615) 0.998(0.987,1.009) 0.555(0.347,0.889) 1.248(0.922,1.689) 1.051(0.731,1.51) 1.014(1.001,1.027) 0.124(0.022,0.702) 0.529(0.153, 1.83) 0.359(0.045,two.857) 0.1(0.959, 1.043) 0.403(0.144,1.124) 0.696(0.345,1.401) 1.132(0.564,two.271) 0.023(0.992,1.055) P-value 0.003** 0.525 0.463 0.728 0.014** 0.152 0.79 0.033** 0.018** 0.314 0.333 0.986 0.083* 0.309 0.727 0.141 Multivariateb Hazard ratio (95 CI) 0.511(0.323, 0.809) 1.026(0.757,1.391) 1.121(0.773,1.624) 0.998(0.987, 1.011) 0.585(0.36, 0.951) 1.13(0.825, 1.548) 1.051(0.715, 1.546) 1.012(0.999,1.025) 0.127(0.021, 0.745) 0.495(0.121, 2.031) ?1.024(0.969, 1.082) 0.345(0.122, 0.972) ?1.333(0.655, two.713) 1.026(0.994, 1.059) P-value 0.004*** 0.868 0.547 0.821 0.031** 0.446 0.801 0.082* 0.022** 0.329 ?0.404 0.044** ?0.428 0.a Univariate logistic regression analysis was performed for each and every in the predictor and clinical variables to predict patient survival immediately after principal and secondary chemotherapies; statistical significance was reported with all round model significance p-value. The median overall survival time in the predicted CRs was 48.two months and that on the predicted NRs was 35.9 months (lo.Vival time PFS Variables predictor score Surgical outcome (Sub vs Optimal) Stage(IV vs II II) Age OS predictor score Surgical outcome (Sub vs Optimal) Stage (IV vs II II) Age Cyclophosphamide TCGA-448 (n = 27) OS predictor score Surgical outcome (Sub vs Optimal) Stage (IV vs II II) Age Topotecan TCGA-test (n = 53) OS predictor score Surgical outcome (Sub vs Optimal) Stage (IV vs II II) Age Hazard ratio (95 CI) 0.515(0.332, 0.798) 1.099(0.821,1.472) 1.14(0.804, 1.615) 0.998(0.987,1.009) 0.555(0.347,0.889) 1.248(0.922,1.689) 1.051(0.731,1.51) 1.014(1.001,1.027) 0.124(0.022,0.702) 0.529(0.153, 1.83) 0.359(0.045,two.857) 0.1(0.959, 1.043) 0.403(0.144,1.124) 0.696(0.345,1.401) 1.132(0.564,2.271) 0.023(0.992,1.055) P-value 0.003** 0.525 0.463 0.728 0.014** 0.152 0.79 0.033** 0.018** 0.314 0.333 0.986 0.083* 0.309 0.727 0.141 Multivariateb Hazard ratio (95 CI) 0.511(0.323, 0.809) 1.026(0.757,1.391) 1.121(0.773,1.624) 0.998(0.987, 1.011) 0.585(0.36, 0.951) 1.13(0.825, 1.548) 1.051(0.715, 1.546) 1.012(0.999,1.025) 0.127(0.021, 0.745) 0.495(0.121, two.031) ?1.024(0.969, 1.082) 0.345(0.122, 0.972) ?1.333(0.655, two.713) 1.026(0.994, 1.059) P-value 0.004*** 0.868 0.547 0.821 0.031** 0.446 0.801 0.082* 0.022** 0.329 ?0.404 0.044** ?0.428 0.a Univariate logistic regression analysis was performed for every single of the predictor and clinical variables to predict patient survival soon after major and secondary chemotherapies; statistical significance was reported with overall model significance p-value. b A multivariate Cox regression analysis was performed with all the predictor and all clinical variables in the exact same model; the statistical significance of every variable was derived from the fitted model. Each OS and PFS have been predicted just after the key platinum-based chemotherapy with paclitaxel, and OS was predicted after the secondary chemotherapy, either with cyclophosphamide or topotecan.
